quantum dots

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Quantum Materials and NanoAxis have forged a deal combining their technologies for diagnostic and pharmaceutical applications.

Quantum Materials and Nanoaxis this week announced a partnership that will see the firms pair their respective technologies to develop microarray-based tests for a variety of conditions.

Building on its experience in different technology areas, the company is currently developing the single-molecule platform, which it plans to start testing next year with external collaborators such as the J. Craig Venter Institute.

Short Reads

Premium

Life Technologies, J. Craig Venter Institute, BioNanomatrix, Nanosys, Geospiza, HDF Group, Pressure BioSciences, Cofactor Genomics, Ambry Genetics, Affymetrix, Navigenics, Enzymatics, New York State Department of Health, University of Washington

Life Technologies is looking to expand uses of its quantum dot technology beyond life sciences and into applied fields, such as counterfeit detection.

Proteins, Front and Center

Premium

Once a tool that only piqued the interest of technology developers, protein microarrays have come into their own as scientists find new ways to apply them in basic and translational studies.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.